Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system
1998

Interleukin 12's Anti-Tumor Effects in Mice with Brain Tumors

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): H Kishima, K Shimizu, Y Miyao, E Mabuchi, K Tamura, M Tamura, M Sasaki, T Hayakawa

Primary Institution: Osaka University Medical School

Hypothesis

Does interleukin 12 have anti-tumor activity against malignant gliomas in the central nervous system?

Conclusion

Systemic interleukin 12 treatment significantly improved survival and induced long-lasting immunity against gliomas in mice.

Supporting Evidence

  • 80% of mice treated with IL-12 were cured and showed no symptoms for over 30 days.
  • IL-12 treatment led to significant infiltration of CD4+ and CD8+ lymphocytes in tumors.
  • Mice cured by IL-12 rejected subsequent challenges with glioma cells.

Takeaway

Interleukin 12 helps mice fight brain tumors by boosting their immune system, making them healthier and able to reject the tumors.

Methodology

Mice with meningeal gliomatosis were treated with interleukin 12 via intraperitoneal or intrathecal administration, and their health was monitored for symptoms and immune response.

Limitations

The study primarily involved mouse models, which may not fully replicate human responses.

Participant Demographics

7-week-old female C3H/HeN and BALB/c-nu/nu mice.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication